MDM2 and breast cancer: We interrogated the candidates for well-developed drug targets and identified MDM2 as the top druggable gene whose knock-down significantly reduced cell viability in the two GATA3-mutant breast cancer cell lines (MCF-7 and KPL-1, Fig. 1c, d).